Earningsreport

Q3/2023 9/30/2023 EPS -0.730 ZacksConsensus -0.950 ActVsEst 0.220 - Beat

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com